Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and Hematologic Malignancies.
Advanced Solid Tumors and Hematologic Malignancies
DRUG: CM369
Adverse events (AEs), 90 weeks|Serious Adverse events (SAEs), 90 weeks|Dose limiting toxicities (DLTs), 90 weeks
PK parameter: Peak Time (Tmax), 90 weeks|PK parameter: Half-life (t1/2), 90 weeks|PK parameter: Area Under the Curve (AUC), 90 weeks|PK parameters: Clearance (CL), 90 weeks|PK parameter: Apparent volume of distribution of steady state (Vss), 90 weeks|Immunogenicity: Incidence of anti-CM369 antibody, 90 weeks
This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and Hematologic Malignancies.